Seema Nagpal
YOU?
Author Swipe
View article: NCOG-62. Real-world use of IDH inhibitors in a Broad IDH-mutant Glioma Population
NCOG-62. Real-world use of IDH inhibitors in a Broad IDH-mutant Glioma Population Open
BACKGROUND Mutant isocitrate dehydrogenase inhibitors (IDHi) have been well-studied in low-grade non-enhancing IDH-mutant (IDHm) gliomas. More work is needed to assess real-world outcomes of IDHi in a wider population of IDHm glioma patien…
View article: Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System–Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes
Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System–Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes Open
For patients with ALK-rearranged NSCLC with leptomeningeal progression or concurrent systemic progression, TKI change or dose increase was a feasible salvage strategy for CNS progression during treatment with CNS-penetrable TKI.
View article: JS05.5.A PATIENT OUTCOMES IN IDH-MUTANT GRADE 2 AND 3 GLIOMAS AFTER DEFERRED OR ADJUVANT RADIOTHERAPY
JS05.5.A PATIENT OUTCOMES IN IDH-MUTANT GRADE 2 AND 3 GLIOMAS AFTER DEFERRED OR ADJUVANT RADIOTHERAPY Open
BACKGROUND Current treatment guidelines for patients with IDH-mutant (IDHm) gliomas recommend radiation (XRT) and chemotherapy following surgery in most cases based on studies in which XRT was compared to XRT plus chemotherapy. Although XR…
View article: Etirinotecan Pegol (<scp>NKTR</scp>‐102) in Patients With Active Brain Metastases From Lung or Breast Cancer
Etirinotecan Pegol (<span>NKTR</span>‐102) in Patients With Active Brain Metastases From Lung or Breast Cancer Open
Background Brain metastases are common in patients with lung and breast cancer and are associated with poor outcomes. While there is some intracranial activity with systemic therapies, most chemotherapies are minimally effective. Etirinote…
View article: A deep learning model to predict glioma recurrence using integrated genomic and clinical data
A deep learning model to predict glioma recurrence using integrated genomic and clinical data Open
View article: Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2a trial of QBS72S in breast cancer brain metastases
Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2a trial of QBS72S in breast cancer brain metastases Open
View article: Faculty of Radiation Oncology 2022 Workforce Census
Faculty of Radiation Oncology 2022 Workforce Census Open
Introduction This paper reports the key findings of the Faculty of Radiation Oncology 2022 workforce census. This is the first census since the COVID‐19 pandemic and questions have been updated to assess the impact on RANZCR trainees and f…
View article: BIOM-04 CSF TUMOR CELL (CSF-TC) DETECTION, QUANTIFICATION AND BIOMARKER ASSESSMENT HELPS IN CLINICAL MANAGEMENT OF BREAST CANCER AND NON-SMALL CELL LUNG CANCER PATIENTS HAVING LEPTOMENINGEAL DISEASE (FORESEE STUDY, NCT05414123)
BIOM-04 CSF TUMOR CELL (CSF-TC) DETECTION, QUANTIFICATION AND BIOMARKER ASSESSMENT HELPS IN CLINICAL MANAGEMENT OF BREAST CANCER AND NON-SMALL CELL LUNG CANCER PATIENTS HAVING LEPTOMENINGEAL DISEASE (FORESEE STUDY, NCT05414123) Open
Leptomeningeal metastases (LM) or the presence of cancer cells in the cerebrospinal fluid (CSF)/pia remains a challenging disease to diagnosis and treat. Current standard of care methods to diagnose or assess treatment response of LM (Clin…
View article: BSLD-07 SIMILAR SURVIVAL IN LEPTOMENINGEAL METASTASES WITH NEGATIVE CSF CYTOLOGY/POSITIVE CNSIDE CIRCULATING TUMOR CELLS VS. POSITIVE CSF CYTOLOGY
BSLD-07 SIMILAR SURVIVAL IN LEPTOMENINGEAL METASTASES WITH NEGATIVE CSF CYTOLOGY/POSITIVE CNSIDE CIRCULATING TUMOR CELLS VS. POSITIVE CSF CYTOLOGY Open
Molecularly targeted therapies are emerging as effective treatments for subtypes of leptomeningeal metastases (LM) with formal clinical trials on the horizon, yet diagnosis of LM remains a challenge because up to 50% of cases have persiste…
View article: BIOM-03 THE ONCOGENIC FLIP IN PATIENTS WITH LEPTOMENINGEAL METASTATIC DISEASE (LMD): LONGITUDINAL DETECTION IN CEREBROSPINAL FLUID TUMOR CELLS (CSF-TCS) REVEALS IMPLICATIONS FOR DIFFERENTIAL TREATMENT OF THE LMD TUMOR
BIOM-03 THE ONCOGENIC FLIP IN PATIENTS WITH LEPTOMENINGEAL METASTATIC DISEASE (LMD): LONGITUDINAL DETECTION IN CEREBROSPINAL FLUID TUMOR CELLS (CSF-TCS) REVEALS IMPLICATIONS FOR DIFFERENTIAL TREATMENT OF THE LMD TUMOR Open
INTRODUCTION Patients with LMD have poor prognosis and limited treatment options. Oncogene amplification of primary, metastatic, and CNS metastatic tumors can be heterogeneous. Therefore, patients with LMD may benefit from assessment of cl…
View article: SRDA-01 DYNAMIC CONTROL OF CEREBROSPINAL FLUID FLOW TO ACHIEVE PERSONALIZED DRUG DELIVERY IN THE CENTRAL NERVOUS SYSTEM
SRDA-01 DYNAMIC CONTROL OF CEREBROSPINAL FLUID FLOW TO ACHIEVE PERSONALIZED DRUG DELIVERY IN THE CENTRAL NERVOUS SYSTEM Open
BACKGROUND Systemically delivered therapeutics have limited access to the brain due to the tightly regulated blood brain barrier. There is a fine balance between production, volume, and removal of cerebrospinal fluid (CSF). The active effl…
View article: Hold Your Fire: The Case for Targeted Therapy, Not Radiation, for EGFR-mutant Non-small Cell Lung Cancer Leptomeningeal Disease
Hold Your Fire: The Case for Targeted Therapy, Not Radiation, for EGFR-mutant Non-small Cell Lung Cancer Leptomeningeal Disease Open
View article: Characteristics and Outcomes of Patients With IDH-Mutant Grade 2 and 3 Gliomas After Deferred or Adjuvant Radiotherapy
Characteristics and Outcomes of Patients With IDH-Mutant Grade 2 and 3 Gliomas After Deferred or Adjuvant Radiotherapy Open
Although retrospective, the marked OS difference between aXRT and dXRT groups suggests that aXRT may be not be as beneficial as what was once thought, especially regarding long-term survival. These results also offer justification for the …
View article: Prescription Drug Coverage of Guideline-Directed Medical Therapy for People Living with Heart Failure with Reduced Ejection Fraction in Canada
Prescription Drug Coverage of Guideline-Directed Medical Therapy for People Living with Heart Failure with Reduced Ejection Fraction in Canada Open
Differences in criteria for drug reimbursement create provincial and territorial variation in access to GDMT in Canada. Coverage criteria include prior medication use and prescriber qualifications, which are not supported by evidence-based…
View article: Consortium for Intracranial Metastasis Academic Research (CIMARa): Global interdisciplinary collaborations to improve outcomes of patients with brain metastases
Consortium for Intracranial Metastasis Academic Research (CIMARa): Global interdisciplinary collaborations to improve outcomes of patients with brain metastases Open
Brain metastases (BrM) arising from solid tumors is an ever-increasing and often devastating clinical challenge impacting hundreds of thousands of patients annually worldwide. As systemic anticancer therapies, and thus survival, improve, t…
View article: A multi-institutional retrospective cohort of adult-onset medulloblastoma in the modern era
A multi-institutional retrospective cohort of adult-onset medulloblastoma in the modern era Open
Background Adult onset medulloblastoma (aMB) is a rare tumor with limited available evidence. We present a large multi-institutional retrospective cohort of aMB patients treated in the modern era, with an emphasis on understanding the role…
View article: Intrathecal pemetrexed for leptomeningeal metastases in a patient with ALK-rearranged lung adenocarcinoma: a case report
Intrathecal pemetrexed for leptomeningeal metastases in a patient with ALK-rearranged lung adenocarcinoma: a case report Open
View article: 1312 The anti-tumor response of BPM31510 is associated with immune cell regulation in the tumor microenvironment
1312 The anti-tumor response of BPM31510 is associated with immune cell regulation in the tumor microenvironment Open
View article: LUNAR: A Deep Learning Model to Predict Glioma Recurrence Using Integrated Genomic and Clinical Data
LUNAR: A Deep Learning Model to Predict Glioma Recurrence Using Integrated Genomic and Clinical Data Open
Gliomas account for approximately 25.5% of all primary brain and central nervous system tumors, with a striking 80.8% of these being malignant. The prognosis varies significantly; low-grade gliomas (LGGs) can exhibit 5-year survival rates …
View article: BMRK-13 CSF TUMOR CELL (CSF-TC) DETECTION, QUANTIFICATION AND BIOMARKER ASSESSMENT HELPS IN CLINICAL MANAGEMENT OF BREAST CANCER AND NON-SMALL CELL LUNG CANCER PATIENTS HAVING LEPTOMENINGEAL DISEASE (FORESEE STUDY, NCT05414123)
BMRK-13 CSF TUMOR CELL (CSF-TC) DETECTION, QUANTIFICATION AND BIOMARKER ASSESSMENT HELPS IN CLINICAL MANAGEMENT OF BREAST CANCER AND NON-SMALL CELL LUNG CANCER PATIENTS HAVING LEPTOMENINGEAL DISEASE (FORESEE STUDY, NCT05414123) Open
Leptomeningeal metastases (LM) in solid tumors is difficult to diagnose and treat, and occurs when there are cancer cells in the cerebrospinal fluid (CSF)/pia and arachnoid. Current standard of care methods to diagnose or assess treatment …
View article: BSLM-05 TRASTUZUMAB DERUXTECAN IN LEPTOMENINGEAL METASTASES FROM HER2-ALTERED CANCERS
BSLM-05 TRASTUZUMAB DERUXTECAN IN LEPTOMENINGEAL METASTASES FROM HER2-ALTERED CANCERS Open
Emerging data suggest that trastuzumab deruxtecan (T-DXd) is a clinically active treatment for brain metastases from HER2+ breast cancer. We aimed to characterize the activity of T-DXd in the treatment of leptomeningeal metastases (LM) fro…
View article: Targeted multiplex validation of CSF proteomic biomarkers: implications for differentiation of PCNSL from tumor-free controls and other brain tumors
Targeted multiplex validation of CSF proteomic biomarkers: implications for differentiation of PCNSL from tumor-free controls and other brain tumors Open
Introduction Primary central nervous system lymphoma (PCNSL) is a rare type of non-Hodgkin’s lymphoma that affects brain parenchyma, eyes, cerebrospinal fluid, and spinal cord. Diagnosing PCNSL can be challenging because imaging studies of…
View article: Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions
Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions Open
Leptomeningeal metastases (LM) are increasingly becoming recognized as a treatable, yet generally incurable, complication of advanced cancer. As modern cancer therapeutics have prolonged the lives of patients with metastatic cancer, specif…
View article: Morvan Fibrillary Chorea Associated with Monoclonal B Cell Lymphocytosis
Morvan Fibrillary Chorea Associated with Monoclonal B Cell Lymphocytosis Open
BACKGROUND Morvan fibrillary chorea (Morvan syndrome) is a rare disorder marked by a collection of neurological symptoms such as myokymia, peripheral nerve excitability, neuromyotonia, autonomic instability, memory impairment, and delirium…
View article: Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis
Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis Open
View article: The HER2 flip-HER2 amplification of tumor cells in the cerebrospinal fluid of breast cancer patients with leptomeningeal disease: implications for treating the LM tumor with anti-HER2 therapy
The HER2 flip-HER2 amplification of tumor cells in the cerebrospinal fluid of breast cancer patients with leptomeningeal disease: implications for treating the LM tumor with anti-HER2 therapy Open
Introduction CNSide is a platform that detects and characterizes tumor cells in the cerebrospinal fluid (CSF) of patients with leptomeningeal disease (LMD). The platform was validated per College of American Pathologists (CAP) and Clinical…
View article: Executive summary of the American Radium Society appropriate use criteria for brain metastases in epidermal growth factor receptor mutated-mutated and ALK-fusion non-small cell lung cancer
Executive summary of the American Radium Society appropriate use criteria for brain metastases in epidermal growth factor receptor mutated-mutated and ALK-fusion non-small cell lung cancer Open
The American Radium Society (ARS) Central Nervous System (CNS) committee reviewed literature on epidermal growth factor receptor mutated (EGFRm) and ALK-fusion (ALK+) tyrosine kinase inhibitors (TKIs) for the treatment of brain metastases …
View article: A complex presentation of hypernatremia complicating hyperosmolar hyperglycemic state (HHS) in a geriatric patient: a case report
A complex presentation of hypernatremia complicating hyperosmolar hyperglycemic state (HHS) in a geriatric patient: a case report Open
View article: A rare non-gadolinium enhancing sarcoma brain metastasis with microenvironment dominated by tumor-associated macrophages
A rare non-gadolinium enhancing sarcoma brain metastasis with microenvironment dominated by tumor-associated macrophages Open
Brain metastases occur in 1% of sarcoma cases and are associated with a median overall survival of 6 months. We report a rare case of a brain metastasis with unique radiologic and histopathologic features in a patient with low grade fibrom…
View article: Quantification of Cerebrospinal Fluid Tumor DNA in Lung Cancer Patients with Suspected Leptomeningeal Carcinomatosis
Quantification of Cerebrospinal Fluid Tumor DNA in Lung Cancer Patients with Suspected Leptomeningeal Carcinomatosis Open
Introduction Cerebrospinal fluid tumor-derived DNA (CSF-tDNA) analysis is a promising approach for monitoring neoplastic processes of the central nervous system. We hypothesize that analysis of CSF-tDNA in patients with advanced lung cance…